We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / PRODUCT PORTFOLIO
OTHER THERAPEUTIC AREAS

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, diseases and pain. 
Product Active Ingredients Dosage form Description Launch date
Noxiall® PEA + Commiphora  Myrrha + Rosmarinus Officinalis + Piper Nigrum (of which Beta Caryophyllene) Box of 20 tablets Useful to contrast chronic and neuropathic pain Jan 2017
Partnena® Magnesium + Parthenium + Andrographis Paniculata + Coenzyme Q10 + Vitamin B2 Box of 28 tablets Rational combination for the prophylaxis of migraine, the nociceptive modulation and the reduction of tension states Jan 2014
Quetidia® oral solution L-Theanine + Passiflora + Skullcap + Magnesium Oral solution. Bottle of 150 ml Useful for the management of anxiety disorders Sep 2017
Seripnol® L-Theanine + Magnolia + Ziziphus + Melatonin Box of 28 sachets Useful to promote relaxation and sleep Mar 2012
Seripnol® drops L-Theanine + Melatonin + Magnolia + Ziziphus Oral drops. Bottle of 30 ml Useful to promote relaxation and sleep Apr 2014


Triadenor® N-Acetyl-Cystein + S-Adenosyl -LMethionine + Folic Acid Box of 16 tablets Useful for the management of depressive disorders Nov 2014
UMP + Folic Acid + B12 Uridine Monophosphate + Folic Acid + Vitamin B12 Box of 20 and 40 film-coated tablets Useful for the treatment of spinal syndromes, neuralgias and polyneuropathies Jul 2018
Vivifast® Citicoline Cognizin® +  Homotaurine + Vitamin E Box of 20 tablets Useful in the management of several types of cognitive disorders Nov 2015
Viviflux® Homotaurine + DHA + Folic Acid Box of 20 capsules Indicated for stroke primary and secondary prevention and for cerebrovascular disorders Sep 2011
Vivimind® Homotaurine Box of 40 tablets Intended to protect memory and cognitive functions in MCI patients Nov 2010
FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.